Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Defender Capital LLC.

Defender Capital LLC. lifted its holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 19.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,963,348 shares of the company's stock after buying an additional 961,150 shares during the quarter. Lineage Cell Therapeutics makes up about 1.1% of Defender Capital LLC.'s portfolio, making the stock its 12th biggest position. Defender Capital LLC. owned 2.71% of Lineage Cell Therapeutics worth $2,997,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its holdings in shares of Lineage Cell Therapeutics by 2.3% in the third quarter. Geode Capital Management LLC now owns 3,679,280 shares of the company's stock worth $3,331,000 after buying an additional 83,274 shares during the period. Barclays PLC grew its stake in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company's stock worth $192,000 after purchasing an additional 159,924 shares in the last quarter. State Street Corp grew its stake in Lineage Cell Therapeutics by 1.8% in the third quarter. State Street Corp now owns 2,608,352 shares of the company's stock worth $2,361,000 after purchasing an additional 45,483 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Lineage Cell Therapeutics by 13.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company's stock valued at $613,000 after acquiring an additional 82,864 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at $61,000. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have commented on LCTX shares. Maxim Group lowered their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, January 10th. D. Boral Capital reissued a "buy" rating and issued a $2.00 price objective on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Finally, HC Wainwright boosted their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, December 4th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $4.80.

Lineage Cell Therapeutics Price Performance

Shares of LCTX stock traded up $0.02 during trading hours on Thursday, reaching $0.62. The company had a trading volume of 425,631 shares, compared to its average volume of 2,430,582. The firm has a market capitalization of $137.54 million, a PE ratio of -5.20 and a beta of 1.18. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.48 and a 12-month high of $1.61.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.